
aug pm et
summari develop small molecul therapeut treatment wide rang diseas led
cystic fibrosi anti-inflammatori condit
nm price-to-earnings oper ep
risk assess reflect view vertex
reliant expand cystic fibrosi cf franchis
wider patient sub-group given may write-down
hepat franchis see clear lead
market rival cf market
fiscal year end dec ep estim base cfra
oper earn histor earn report
cash dividend paid last year
past perform indic futur perform reli upon
analysi prepar equiti analyst
aug stock trade
orkambi sale rose
kalydeco sale rose
total cystic
fibrosi cf product sale rose
look continu robust
double-digit product sale growth see
sale billion februari
symdeko receiv fda approv treat cf
patient age older two
copi mutat
least one mutat respons
tezacraftor/ivacaftor expect symdeko
receiv european approv
juli receiv fda approv
orkambi treat underli caus
cystic fibrosi approv signific
mileston event gener
billion dollar sale enabl
becom clear market leader
treatment cf septemb orkambi
approv treat children two
copi mutat approxim
children age elig
treatment
fda action date august
kalydeco patient age
august fda action date
orkambi patient age
believ current serv
elig cf patient peopl
cf compani believ elig
popul increas peopl
label expans includ
children age
europ reimburs orkambi
recent approv symdeko also believ
tripl combin regimen treat cf
opportun cf popul
patient trial current
phase success meet primari end
point think could potenti file
nda tripl combin regimen mid
risk opinion target price includ
failur expand cf franchis
greater-than-expect discount orkambi
kalydeco payer pushback pipelin
failur clinic trial failur non-approv
regulatori file
target base
line peer ratio forward
ep estim
anticip continu robust sale growth
obtain addit price
reimburs deal countri
cf drug
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
execut vice-president chief
corpor overview biotechnolog compani focus discoveri
develop breakthrough small molecul drug seriou diseas compani product pipelin
focus viral diseas cystic fibrosi inflamm autoimmun diseas epilepsi
partnership cystic fibrosi foundat studi novel small molecul
treatment cystic fibrosi cf rare respiratori diseas afflict roughli patient world-wide
lead candid oral dose kalydeco approv januari treat adult cf
patient rare mutat repres around total patient popul
drug approv europ juli
orkambi lumacaftor combin ivacaftor approv unit state food drug
administr fda european commiss treatment patient cf
year age older two copi homozyg mutat cf
transmembran conduct regul cftr gene compani complet first two phase
clinic trial evalu lumacaftor combin ivacaftor treatment patient cf six
year age homozyg mutat cftr gene
kalydeco ivacaftor orally-administ cftr potenti approv unit state
european union australia canada treatment certain patient cf specif
mutat cftr gene unit state kalydeco approv treatment patient
cf two year age older one mutat cftr gene includ
european union
kalydeco approv treatment patient cf two year age older one
follow mutat cftr gene
year age older mutat cftr gene
symdeko tezacaftor/ivacaftor ivacaftor approv fda februari therapi
cystic fibrosi cf patient carri two copi mutat cftr gene gene
defect cf one mutat respond tezacaftor/ivacaftor symdeko third
product approv cf patient
pipelin compani multipl develop program field cf includ
tripl combin regimen current phase clinic trial
beyond cf pain program includ select inhibitor repres first
proof concept inhibit treatment acut pain chronic inflammatori pain
phase ii result third type pain neuropath pain expect earli howev
stop develop base pharmacokinet toler find
also partner crispr advanc first gene edit treatment
sickl cell diseas beta-thalassemia use technolog beta-thalassemia
obtain approv clinic trial applic cta earli
obtain cta approv canada expect initi first studi
beta-thalassemia late sickl cell diseas obtain cta approv canada
howev continu work fda address agenc question regard ind
submit earli
impact major develop juli receiv fda approv orkambi treat
underli caus cystic fibrosi approv signific mileston event
gener billion dollar sale enabl becom clear market leader treatment
cf septemb orkambi approv treat children two copi
mutat approxim children age elig treatment kalydeco
approv januari treat adult cf patient rare mutat
repres around total patient popul drug approv europ juli
end sale distribut hepat drug incivek follow success gilead
scienc hepat drug sovaldi incivek approv sale billion
howev sale start declin earli physician patient await approv
sovaldi much better efficaci rate
financi trend sale consist almost exclus cf drug rose million
billion repres three-year compound annual growth rate compound-annual-growth-rate
adjust earn loss per share develop cost exceed revenu becam
profit achiev ep ep doubl first
turn profit adjust ep driven success hepat drug incivek
howev end incivek sale due success compet product
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
overvalu
bullish sinc june technic indic
bullish
figur base fiscal year-end price
growth rate averag
return equiti
balanc sheet data million
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
posit fundament outlook
biotechnolog sub-industri next
month reflect favor prospect new
novel therapi reach commerci yet
anticip modest overal
sale growth mainli due forecast
mid-teen sale declin
biotech sale rose low singl
digit follow growth
follow robust growth period
compound annual growth
rate think sale growth
somewhat limit heighten focu high
drug price encourag view
strong period report
late-stag clinic result
accommod fda approv
fda approv new drug --
sinc record approv
howev fda approv
new drug significantli robust
new drug approv think mani
newly-approv drug signific
commerci prospect repres major
advanc therapi diseas
sclerosi cancer fda
approv first time gene-therapi drug
involv remov patient immun cell
genet alter alter
cell re-introduc patient
help fight cancer
expect wider adopt biomark research
genetic-target clinic studi help
late fda introduc breakthrough
therapi design intend speed
develop promis program expect
favor merger acquisit climat
larg pharmaceut firm move off-set
lost revenu expir drug patent
larg biotech bolster drug pipelin amid
larger scale acquisit
fda author govern biosimilar
drug approv set exclus
advanc modest rate next
sever year see improv
biosimilar approv introduc
march fda approv novarti
filgrastim biosimilar version
novarti began sell
biosimilar name zarxio septemb
april fda approv
inflectra manufactur celltrion
co-market inflectra
biosimilar johnson johnson
expect biosimilar sell modest price
discount gener pharmaceut
industri due higher clinic manufactur
market cost expect brand
drug retain signific market share due
lack interchang think
biosimilar may appeal new user
expect current user stabl
current treatment would like continu
refer drug howev note
prescript benefit manag health
insur exert influenc drug
prescript price
remov neupogen formulari
replac zarxio
 biotech index rose vs
rise year date
juli biotech index
rose vs rise
base index
five-year market price perform aug
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
impress result past posit data
et capit iq keep hold opinion share vertex
share posit data two
phase studi combin kalydeco treat cystic
fibrosi cf studi met primari end-point show
signific improv lung function evolv studi evalu patient
two copi mutat show improv
expand studi evalu patient one mutat show
improv plan file nda see combin
drive cf sale rais target in-lin
analyst research note compani news
pharmaceut incorpor rais
target price line peer ratio base
forward ep estim anticip continu robust sale
growth obtain addit price reimburs agreement
countri cystic fibrosi cf drug also believ tripl
combin regimen treat cf could significantli expand market
opportun trial current phase success meet
primari end point think could potenti file nda
tripl combin regimen also two pend fda action
date august expand cf treatment younger patient ep
vs ahead estim rais ep
estim ep estim sale rose
driven success launch symdeko addit
countri agre price reimburs cf drug /jeffrey
et cfra keep buy opinion share vertex
pharmaceut incorpor keep
target above-p ratio due view robust
growth prospect base ep estim ep
vs ahead view sale cystic fibrosi
cf product rose aid launch symdeko solid growth
kalydeco orkambi symdeko receiv fda approv
treat cf patient age two copi mutat
least one mutat respons tezacraftor/ivacaftor
expect symdeko receiv eu approv believ
cf patient world-wide elig product half
patient product see signific growth potenti
pend approv cf product patient age
fda action date august kalydeco patient age
august fda action date orkambi patient age
et cfra reiter buy opinion share vertex
pharmaceut incorpor rais
target above-p ratio robust growth prospect
rais ep estim set ep
vs ahead view cystic fibrosi cf product
sale grew orkambi kalydeco
tezacaftor/ivacaftor combin fda action date februari
expect approv select advanc phase
develop part two differ tripl combin regimen
think could treat cf patient /jeffrey loo cfa
et cfra rais opinion share vertex
inc buy hold keep target
peer ratio robust growth prospect cystic fibrosi
cf franchis sale cf drug rose orkambi kalydeco
ep vs ahead view rais
ep estim report mix
result phase trial orkambi children age meet
end-point trial evalu tezacaftor meet end-point
howev view tripl combin drug next catalyst cf
inc rais target
peer share today releas data
separ compound use tripl drug combin approv
drug current treat cystic fibrosi cf patient
believ could treat cf patient tripl combin
drug separ phase ii combin studi improv lung
function phase trial improv lung function
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
